Pure Global AI
NCT03015220Completed

Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes

Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD in Japanese Subjects With Type 2 Diabetes
Novo Nordisk A/SPhase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Diabetes,Diabetes Mellitus, Type 2
Drug/Device/Intervention
Semaglutide
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Novo Nordisk A/S
Location
Adachi-ku, Tokyo,Annaka-shi, Gunma,Arakawa-ku, Tokyo,Chiba-shi, Chiba,Chuo-ku, Tokyo,Fukushima,Gunma,Ibaraki,Iruma-shi, Saitama,Kanagawa,Kashiwara-shi, Osaka,Kawagoe-shi, Saitama,Kawaguchi-shi, Saitam, Japan
Timeline & enrollment
Phase
Phase 3
Start date
Jan 10, 2017
End date
Jul 12, 2018
Enrollment
458 participants
Primary outcome

Number of Treatment-emergent Adverse Events (TEAEs)

Summary

This trial is conducted in Asia. The aim of this trial is to investigate Safety and efficacy
 of oral semaglutide versus dulaglutide both in combination with one OAD (oral antidiabetic
 drug) in Japanese subjects with type 2 diabetes.

ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03015220
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT03015220 through Pure Global AI's free database. This Phase 3 trial is sponsored by Novo Nordisk A/S and is currently Completed. The study focuses on Diabetes,Diabetes Mellitus, Type 2. Target enrollment is 458 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.